Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA

  • The PLOS ONE Staff
  • Article
  • Metrics
  • Comments
  • Media Coverage

Notice of Republication

This article was republished on August 7, 2015, to replace Fig 2, which was incorrect. The publisher apologizes for the error. Please download this article again to view the correct version.

Reference

  1. 1. Ferreira A, Sagkriotis A, Olson M, Lu J, Makin C, Milnes F (2015) Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA. PLoS ONE 10(7): e0133968. pmid:26208030

Citation: The PLOS ONE Staff (2015) Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA. PLoS ONE 10(8): e0136515. https://doi.org/10.1371/journal.pone.0136515

Published: August 21, 2015

Copyright: © 2015 The PLOS ONE Staff. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited